229 related articles for article (PubMed ID: 10935183)
1. Search for newer antileprosy drugs.
Dhople AM
Indian J Lepr; 2000; 72(1):5-20. PubMed ID: 10935183
[TBL] [Abstract][Full Text] [Related]
2. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Matsuoka M; Kashiwabara Y; Namisato M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
Dhople AM; Lamoureux LC; Gardner GD
Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
[TBL] [Abstract][Full Text] [Related]
4. Newer drugs in leprosy.
Grosset JH
Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
[TBL] [Abstract][Full Text] [Related]
6. Study of rifampicin resistance and comparison of dapsone resistance of M. leprae in pre- and post-MDT era.
Gupta UD; Katoch K; Katoch VM
Indian J Lepr; 2009; 81(3):131-4. PubMed ID: 20509341
[TBL] [Abstract][Full Text] [Related]
7. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
Dhople AM
Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
[TBL] [Abstract][Full Text] [Related]
9. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads.
Dhople AM; Ortega I; Seydel JK; Gardner GD
Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
Ji B; Perani EG; Petinon C; Grosset JH
Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):556-61. PubMed ID: 1338596
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
Dhople AM; Dimova V
Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
[TBL] [Abstract][Full Text] [Related]
12. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
Dhople AM; Ibanez MA
Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
Dhople AM
Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
[TBL] [Abstract][Full Text] [Related]
14. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae.
Cambau E; Perani E; Guillemin I; Jamet P; Ji B
Lancet; 1997 Jan; 349(9045):103-4. PubMed ID: 8996430
[No Abstract] [Full Text] [Related]
16. Assessment of viability by normal mouse foot-pad and bacillary ATP bioluminescence assay in multibacillary cases treated with an MDT regimen using conventional as well as newer drugs like minocycline and ofloxacin.
Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
Indian J Lepr; 2000; 72(4):437-42. PubMed ID: 11212477
[TBL] [Abstract][Full Text] [Related]
17. The mouse foot-pad technique for cultivation of Mycobacterium leprae.
Levy L; Ji B
Lepr Rev; 2006 Mar; 77(1):5-24. PubMed ID: 16715686
[TBL] [Abstract][Full Text] [Related]
18. In vitro resistance test of human leprosy bacilli to anti-leprous drugs.
Ishihara S; Hagiwara S; Fujuda T
Microbios; 1977; 19(76):117-23. PubMed ID: 366337
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
[TBL] [Abstract][Full Text] [Related]
20. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
Ji BH; Chen JK; Lu XZ; Wang SY; Ni GX; Hou YH; Zhou DH; Tang QK
Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
